Candel Therapeutics, Inc. (CADL)
- Previous Close
5.2800 - Open
5.2300 - Bid 4.9400 x 900
- Ask 5.0700 x 900
- Day's Range
4.8700 - 5.2700 - 52 Week Range
3.7850 - 14.6000 - Volume
996,565 - Avg. Volume
1,151,405 - Market Cap (intraday)
235.233M - Beta (5Y Monthly) -0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-1.7400 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the?enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
www.candeltx.comRecent News: CADL
View More
Performance Overview: CADL
Trailing total returns as of 5/5/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CADL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CADL
View MoreValuation Measures
Market Cap
235.23M
Enterprise Value
146.05M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.55
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.55%
Return on Equity (ttm)
-139.56%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-55.18M
Diluted EPS (ttm)
-1.7400
Balance Sheet and Cash Flow
Total Cash (mrq)
102.65M
Total Debt/Equity (mrq)
20.31%
Levered Free Cash Flow (ttm)
7.38M
Research Analysis: CADL
View MoreResearch Reports: CADL
View MoreDaily – Vickers Top Insider Picks for 03/08/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/07/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/06/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.
Daily – Vickers Top Insider Picks for 03/03/2023
The Vickers Top Insider Picks is a daily report that utilizes a proprietary algorithm to identify 25 companies with compelling insider purchase histories based on transactions over the past three months.